BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411. [PMID: 27575311 DOI: 10.1016/j.jhep.2016.08.009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 150] [Article Influence: 26.2] [Reference Citation Analysis]
Number Citing Articles
1 Cornberg M, Glebe D. Editorial: which factors influence HBsAg levels in HBV-infected patients? Aliment Pharmacol Ther 2020;52:547-8. [DOI: 10.1111/apt.15864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol 2022;76:1249-62. [PMID: 35589248 DOI: 10.1016/j.jhep.2021.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
4 Bertoletti A, Boni C. HBV antigens quantity: duration and effect on functional cure. Gut 2021:gutjnl-2021-326258. [PMID: 34799373 DOI: 10.1136/gutjnl-2021-326258] [Reference Citation Analysis]
5 Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2021:gutjnl-2021-324646. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
6 Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021;74:283-92. [PMID: 32931877 DOI: 10.1016/j.jhep.2020.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Jeng WJ, Liaw YF. Serum HBsAg kinetics in clinical prediction. J Hepatol 2017;67:192-3. [PMID: 28315712 DOI: 10.1016/j.jhep.2017.01.036] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, Pourkarim MR, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212-24. [PMID: 32100261 DOI: 10.1007/s12072-020-10015-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
10 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
11 Linn YH, Ei WW, Myint LMM, Lwin KM. Anti-hepatitis B activities of Myanmar medicinal plants: a narrative review of current evidence. Virusdisease 2021;32:446-66. [PMID: 34631974 DOI: 10.1007/s13337-021-00714-2] [Reference Citation Analysis]
12 Choi GH, Kim G, Choi J, Han S, Lim Y. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [DOI: 10.1111/apt.15311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
13 Cornberg M, Manns MP. Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA? Nat Rev Gastroenterol Hepatol 2018;15:195-6. [PMID: 29382951 DOI: 10.1038/nrgastro.2017.185] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017;31:2035-52. [PMID: 28692539 DOI: 10.1097/QAD.0000000000001574] [Cited by in Crossref: 120] [Cited by in F6Publishing: 71] [Article Influence: 24.0] [Reference Citation Analysis]
15 Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Peng S, Wan Z, Liu T, Wang Y, Chen H, Li X, Du Y. Quantitative Hepatitis B Surface Antigen Predicts Hepatitis B Transmission in Infants Born to e Antigen-positive Mothers. J Clin Gastroenterol 2020;54:76-82. [PMID: 30575631 DOI: 10.1097/MCG.0000000000001158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736 [PMID: 29456411 DOI: 10.3748/wjg.v24.i6.725] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Yeh ML, Yu ML. Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey". J Hepatol 2020;73:462. [PMID: 32327360 DOI: 10.1016/j.jhep.2020.03.041] [Reference Citation Analysis]
20 Riveiro-Barciela M, Pericàs JM, Buti M. How to interpret viral markers in the management of chronic hepatitis B infection. Clin Microbiol Infect 2021:S1198-743X(21)00622-4. [PMID: 34768018 DOI: 10.1016/j.cmi.2021.10.020] [Reference Citation Analysis]
21 Ahmad G, Khan MA, Abbas S, Athar A, Khan BS, Aslam MS. Automated Diagnosis of Hepatitis B Using Multilayer Mamdani Fuzzy Inference System.J Healthc Eng. 2019;2019:6361318. [PMID: 30867895 DOI: 10.1155/2019/6361318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
22 Wang J, Yu Y, Li G, Shen C, Li J, Chen S, Zhang X, Zhu M, Zheng J, Song Z, Wu J, Shao L, Meng Z, Wang X, Huang Y, Zhang J, Qiu C, Zhang W. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat. 2018;25:1038-1047. [PMID: 29633430 DOI: 10.1111/jvh.12908] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
23 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
24 Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 2017;37:1642-1650. [PMID: 28345181 DOI: 10.1111/liv.13432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lee HL, Jang JW, Han JW, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Lee JW. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Dig Dis Sci 2019;64:2992-3000. [PMID: 30982209 DOI: 10.1007/s10620-019-05614-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Yoo EH, Cho HJ. Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients. Clin Chim Acta 2017;471:308-13. [PMID: 28687350 DOI: 10.1016/j.cca.2017.06.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
27 Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. J Viral Hepat 2018;25:886-93. [DOI: 10.1111/jvh.12889] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
28 Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis 2020;70:1442-52. [PMID: 31102406 DOI: 10.1093/cid/ciz412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
29 Tatar B, Acar A, Adar P, Kose S. Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients. Clin Exp Hepatol 2020;6:55-9. [PMID: 32166125 DOI: 10.5114/ceh.2020.93058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B; HIDIT-II Study Group. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun 2021. [PMID: 34561972 DOI: 10.1002/hep4.1821] [Reference Citation Analysis]
31 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
32 Lin TC, Liu WC, Hsu YH, Lin JJ, Chiu YC, Chiu HC, Cheng PN, Chen CY, Chang TT, Wu IC. Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. J Clin Med 2019;8:E1892. [PMID: 31698809 DOI: 10.3390/jcm8111892] [Reference Citation Analysis]
33 Gani AW, Wei W, Shi RZ, Ng E, Nguyen M, Chua MS, So S, Wang SX. An Automated, Quantitative, and Multiplexed Assay Suitable for Point-of-Care Hepatitis B Virus Diagnostics. Sci Rep 2019;9:15615. [PMID: 31666635 DOI: 10.1038/s41598-019-52147-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
34 Prakash K, Rydell GE, Larsson SB, Andersson M, Norkrans G, Norder H, Lindh M. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86. [PMID: 29764511 DOI: 10.1186/s12985-018-0994-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
35 Zeng DW, Huang ZX, Lin MX, Kang NL, Lin X, Li YN, Zhu YY, Liu YR. A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211010675. [PMID: 34104207 DOI: 10.1177/17562848211010675] [Reference Citation Analysis]
36 Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Reference Citation Analysis]
37 Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, Cao Z, Ren S, Ma L, Jin Y, Zheng S, Hu Z, Wang L, Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med 2021;9:1365. [PMID: 34733917 DOI: 10.21037/atm-21-1666] [Reference Citation Analysis]
38 Basic M, Kubesch A, Kuhnhenn L, Görgülü E, Finkelmeier F, Dietz J, Knabe M, Mücke VT, Mücke MM, Berger A, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH. Not uncommon: HBV genotype G co-infections among healthy European HBV carriers with genotype A and E infection. Liver Int 2021;41:1278-89. [PMID: 33786970 DOI: 10.1111/liv.14884] [Reference Citation Analysis]
39 Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology 2021;74:2395-409. [PMID: 34133774 DOI: 10.1002/hep.32018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
40 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Cho HJ, Shin SK, Kwon OS, Kim JH, Kim YS. Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss. Korean J Gastroenterol 2020;76:256-60. [PMID: 33234774 DOI: 10.4166/kjg.2020.111] [Reference Citation Analysis]
42 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, Koek GH, Nevens F. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol 2020. [PMID: 32343427 DOI: 10.1002/jmv.25950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E. Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. J Infect Dis 2018;218:114-23. [PMID: 29528436 DOI: 10.1093/infdis/jiy119] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
45 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Brunetto MR, Cavallone D. Editorial: which factors influence HBsAg levels in HBV-infected patients? Authors' reply. Aliment Pharmacol Ther 2020;52:549-50. [PMID: 32656824 DOI: 10.1111/apt.15910] [Reference Citation Analysis]
47 Chen L, Shi J, Lu Z, Ye Y, Zhou X, Tan Y. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase. Clin Res Hepatol Gastroenterol 2019;43:310-6. [PMID: 30528063 DOI: 10.1016/j.clinre.2018.10.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clin Liver Dis (Hoboken) 2018;12:5-11. [PMID: 30988902 DOI: 10.1002/cld.729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
49 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
50 Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol 2021;205:106-18. [PMID: 33969474 DOI: 10.1111/cei.13614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z, Semenakova-Cvetkovska V, Orovcanec N. Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2018;6:1052-8. [PMID: 29983800 DOI: 10.3889/oamjms.2018.122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Joshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatol Commun. 2020;4:157-171. [PMID: 32025602 DOI: 10.1002/hep4.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
53 Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, Lin H, Hou M, Peng C, Huang Y. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. The Journal of Infectious Diseases 2018;218:1075-84. [DOI: 10.1093/infdis/jiy272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
54 Dimech W. The Standardization and Control of Serology and Nucleic Acid Testing for Infectious Diseases. Clin Microbiol Rev 2021;:e0003521. [PMID: 34319148 DOI: 10.1128/CMR.00035-21] [Reference Citation Analysis]
55 van Campenhout MJH, Rijckborst V, Brouwer WP, van Oord GW, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:1156-63. [PMID: 31135084 DOI: 10.1111/jvh.13117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
57 Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat? Liver Int. 2018;38 Suppl 1:71-78. [PMID: 29427495 DOI: 10.1111/liv.13631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
58 Tao Y, Wang M, Liao J, Cheng X, He M, Zhang D, Zhou T, Chen J, Chen E, Tang H. Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy. Front Med 2022;9:787770. [DOI: 10.3389/fmed.2022.787770] [Reference Citation Analysis]
59 He L, Su M, Ou G, Wang L, Deng J, Zhuang H, Xiang K, Li T. The modulation of HBsAg level by sI126T is affected by additional amino acid substitutions in the S region of HBV. Infect Genet Evol 2019;75:104006. [PMID: 31442597 DOI: 10.1016/j.meegid.2019.104006] [Reference Citation Analysis]
60 Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther 2019;17:943-55. [PMID: 31738607 DOI: 10.1080/14787210.2019.1694906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
61 Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018;50:944-953. [PMID: 29735294 DOI: 10.1016/j.dld.2018.03.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
62 Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Reference Citation Analysis]
63 Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K, Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study. Biomed Rep 2021;14:20. [PMID: 33335726 DOI: 10.3892/br.2020.1396] [Reference Citation Analysis]
64 Zhou T, Block T, Liu F, Kondratowicz AS, Sun L, Rawat S, Branson J, Guo F, Steuer HM, Liang H, Bailey L, Moore C, Wang X, Cuconatti A, Gao M, Lee ACH, Harasym T, Chiu T, Gotchev D, Dorsey B, Rijnbrand R, Sofia MJ. HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. Antiviral Res. 2018;149:191-201. [PMID: 29133129 DOI: 10.1016/j.antiviral.2017.11.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
65 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
66 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
67 Murata A, Angata K, Sogabe M, Sato S, Ichida T, Narimatsu H, Genda T. Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy. BMC Gastroenterol 2022;22:270. [PMID: 35641912 DOI: 10.1186/s12876-022-02352-4] [Reference Citation Analysis]
68 Du Y, Anastasiou OE, Strunz B, Scheuten J, Bremer B, Kraft A, Kleinsimglinhaus K, Todt D, Broering R, Hardtke-Wolenski M, Wu J, Yang D, Dittmer U, Lu M, Cornberg M, Björkström NK, Khera T, Wedemeyer H. The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. Liver Int 2021;41:2046-58. [PMID: 33794040 DOI: 10.1111/liv.14885] [Reference Citation Analysis]
69 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Reference Citation Analysis]
70 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
71 Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZ, Ahmad R, Cheng Y, Dutertre C, Heinecke A, Rivino L, Tan A, Hansi NK, Zhang M, Xi S, Chong Y, Pflanz S, Newell EW, Kennedy PT, Bertoletti A. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology 2020;159:652-64. [DOI: 10.1053/j.gastro.2020.04.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
72 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-99. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1550] [Cited by in F6Publishing: 1255] [Article Influence: 387.5] [Reference Citation Analysis]
73 Wang ML, Chen EQ, Tao CM, Zhou TY, Liao J, Zhang DM, Wang J, Tang H. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy. Scand J Gastroenterol. 2017;52:1420-1426. [PMID: 28880694 DOI: 10.1080/00365521.2017.1374450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
74 Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827-844. [PMID: 31455905 DOI: 10.1038/s41573-019-0037-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 130] [Article Influence: 39.3] [Reference Citation Analysis]
75 Bartenschlager R, Cornberg M, Pietschmann T. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. Internist (Berl) 2017;58:666-74. [PMID: 28631044 DOI: 10.1007/s00108-017-0262-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerg Microbes Infect 2020;9:928-39. [PMID: 32312174 DOI: 10.1080/22221751.2020.1757998] [Reference Citation Analysis]
77 Huang DQ, Kew GS, Lim SG. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer. Clin Liver Dis 2021;25:763-84. [PMID: 34593152 DOI: 10.1016/j.cld.2021.06.005] [Reference Citation Analysis]
78 Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019;69:1816-27. [PMID: 30362148 DOI: 10.1002/hep.30325] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 28.7] [Reference Citation Analysis]
79 Liang LY, Wong VW, Toyoda H, Tse YK, Yip TC, Yuen BW, Tada T, Kumada T, Lee HW, Lui GC, Chan HL, Wong GL. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 2020;55:899-908. [PMID: 32556643 DOI: 10.1007/s00535-020-01700-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
80 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
81 Brunetto MR. Hepatitis B Virus RNA Detection and a Mindful Use of Serum Hepatitis B Virus DNA and Hepatitis B Surface Antigen Measures in Clinical Practice. Hepatol Commun 2020;4:949-52. [PMID: 32626828 DOI: 10.1002/hep4.1554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ding Y, Zhou Z, Li X, Zhao C, Jin X, Liu X, Wu Y, Mei X, Li J, Qiu J, Shen C. Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes. Front Immunol 2022;13:847105. [PMID: 35464415 DOI: 10.3389/fimmu.2022.847105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Peiffer KH, Spengler C, Basic M, Jiang B, Kuhnhenn L, Obermann W, Zahn T, Glitscher M, Loglio A, Facchetti F, Carra G, Kubesch A, Vermehren J, Knop V, Graf C, Dietz J, Finkelmeier F, Herrmann E, Trebicka J, Grünweller A, Zeuzem S, Sarrazin C, Lampertico P, Hildt E. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight 2020;5:135833. [PMID: 33055418 DOI: 10.1172/jci.insight.135833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 43.0] [Reference Citation Analysis]
86 Lee JH, Lee YB, Cho EJ, Yu SJ, Yoon JH, Kim YJ. Entecavir Plus Pegylated Interferon and Sequential HBV Vaccination Increases HBsAg Seroclearance: A Randomized Controlled Proof-of-Concept Study. Clin Infect Dis 2020:ciaa807. [PMID: 32556157 DOI: 10.1093/cid/ciaa807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int 2021;15:290-300. [PMID: 33638770 DOI: 10.1007/s12072-021-10137-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
88 Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer 2021;21:1103. [PMID: 34649509 DOI: 10.1186/s12885-021-08483-3] [Reference Citation Analysis]
89 Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Ou G, He L, Wang L, Song J, Lai X, Tian X, Wang L, Zhang K, Zhang X, Deng J, Zhuang H, Xiang K, Li T. The Genotype (A to H) Dependent N-terminal Sequence of HBV Large Surface Protein Affects Viral Replication, Secretion and Infectivity. Front Microbiol 2021;12:687785. [PMID: 34305848 DOI: 10.3389/fmicb.2021.687785] [Reference Citation Analysis]
91 Wong GL, Wong VW, Chan HL. Towards finite oral antiviral treatment for chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:260-2. [PMID: 30795959 DOI: 10.1016/S2468-1253(19)30045-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
92 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
93 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Quijano-Rubio A, Yeh HW, Park J, Lee H, Langan RA, Boyken SE, Lajoie MJ, Cao L, Chow CM, Miranda MC, Wi J, Hong HJ, Stewart L, Oh BH, Baker D. De novo design of modular and tunable allosteric biosensors. bioRxiv 2020:2020. [PMID: 32743576 DOI: 10.1101/2020.07.18.206946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
96 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Reference Citation Analysis]
97 Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, Loo CK, Chim AML, Tse CH, Wong VWS. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat 2019;26:126-35. [DOI: 10.1111/jvh.13000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
98 Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc 2021;120:1676-85. [PMID: 33339708 DOI: 10.1016/j.jfma.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Vaillant A. HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection. ACS Infect Dis 2021;7:1351-68. [PMID: 33302622 DOI: 10.1021/acsinfecdis.0c00638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
100 Rydell GE, Prakash K, Larsson SB, Skoglund C, Ringlander J, Andersson M, Castedal M, Norder H, Lindh M. Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection. J Infect Dis 2021:jiab469. [PMID: 34534318 DOI: 10.1093/infdis/jiab469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Wu CF, Fong TM, Wu SS, Saab S. Hepatitis B Surface Antigen Levels Are Related to Spontaneous Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers. J Clin Gastroenterol 2020;54:573-6. [PMID: 32049690 DOI: 10.1097/MCG.0000000000001324] [Reference Citation Analysis]
102 Lang-Meli J, Neumann-Haefelin C, Thimme R. Immunotherapy and therapeutic vaccines for chronic HBV infection. Curr Opin Virol 2021;51:149-57. [PMID: 34710645 DOI: 10.1016/j.coviro.2021.10.002] [Reference Citation Analysis]
103 Ringlander J, Skoglund C, Prakash K, Andersson ME, Larsson SB, Tang KW, Rydell GE, Abrahamsson S, Castedal M, Norder H, Hellstrand K, Lindh M. Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA. J Viral Hepat 2020;27:1162-70. [PMID: 32592629 DOI: 10.1111/jvh.13356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Kho-herman SGR, Chan HL. Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when? Liver Research 2017;1:135-9. [DOI: 10.1016/j.livres.2017.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
105 Cheung KW, Lao TT. Hepatitis B - Vertical transmission and the prevention of mother-to-child transmission. Best Pract Res Clin Obstet Gynaecol 2020;68:78-88. [PMID: 32249130 DOI: 10.1016/j.bpobgyn.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
107 Zhang L, Li MH, Yi W, Lu Y, Wu S, Hao H, Gao Y, Lu H, Chen Q, Shen G, Chang M, Hu L, Liu R, Sun L, Wan G, Xie Y. AST and HBeAg Level Can Help to Distinguish Non-Minimal Liver Inflammation in Persistently Normal Alanine Aminotransferase of Chronic HBV Infection. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.99580] [Reference Citation Analysis]
108 Shah AS, Civelli VF, Bali V, Johnson RH, Heidari A. A Case of S-Variant Hepatitis B Virus: An Immune System Escape Artist. J Investig Med High Impact Case Rep 2021;9:23247096211045450. [PMID: 34521227 DOI: 10.1177/23247096211045450] [Reference Citation Analysis]
109 Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Reference Citation Analysis]
110 Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol 2021:S0168-8278(21)00328-7. [PMID: 34004216 DOI: 10.1016/j.jhep.2021.04.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Shokr A, Pacheco LGC, Thirumalaraju P, Kanakasabapathy MK, Gandhi J, Kartik D, Silva FSR, Erdogmus E, Kandula H, Luo S, Yu XG, Chung RT, Li JZ, Kuritzkes DR, Shafiee H. Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano 2021;15:665-73. [PMID: 33226787 DOI: 10.1021/acsnano.0c06807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
112 Cai Y, Yan J, Zhu L, Wang H, Lu Y. A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen. Biosensors (Basel) 2020;10:E161. [PMID: 33142715 DOI: 10.3390/bios10110161] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
114 Lu F, Wang J, Chen X, Xu D, Xia N. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med 2017;11:502-8. [PMID: 29170915 DOI: 10.1007/s11684-017-0590-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
115 Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Journal of Hepatology 2019;70:615-25. [DOI: 10.1016/j.jhep.2018.11.030] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 28.0] [Reference Citation Analysis]
116 Zhong YW, Shi YM, Chu F, Liu J, Shi C, Xu JJ, Liu P, Bai YJ, Xiao XH, Zhang XC, Zhang M. Prediction for HBsAg seroconversion in children with chronic hepatitis B. BMC Infect Dis 2021;21:1211. [PMID: 34863101 DOI: 10.1186/s12879-021-06883-1] [Reference Citation Analysis]
117 Cavallone D, Ricco G, Oliveri F, Colombatto P, Moriconi F, Coco B, Romagnoli V, Salvati A, Surace L, Bonino F, Brunetto MR. Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection? Aliment Pharmacol Ther 2020;51:1406-16. [PMID: 32390175 DOI: 10.1111/apt.15753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
118 Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
119 Rinker F, Bremer CM, Schröder K, Wiegand SB, Bremer B, Manns MP, Kraft AR, Wedemeyer H, Yang L, Pavlovic V, Wat C, Gerlich WH, Glebe D, Cornberg M. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Liver Int 2020;40:324-32. [PMID: 31721419 DOI: 10.1111/liv.14298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
120 Loggi E, Vukotic R, Conti F, Grandini E, Gitto S, Cursaro C, Galli S, Furlini G, Re MC, Andreone P. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:568-75. [PMID: 30576048 DOI: 10.1111/jvh.13054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
121 Chuaypen N, Payungporn S, Poovorawan K, Chotiyaputta W, Piratvisuth T, Tangkijvanich P. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes 2019;55:610-8. [PMID: 31359359 DOI: 10.1007/s11262-019-01689-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
122 Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]
123 Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc 2021;120:847-53. [PMID: 32896456 DOI: 10.1016/j.jfma.2020.08.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
124 Zhang ZQ, Wang YB, Lu W, Liu DP, Shi BS, Zhang XN, Huang D, Li XF, Zhou XL, Ding RR. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis. Ann Lab Med 2019;39:67-75. [PMID: 30215232 DOI: 10.3343/alm.2019.39.1.67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
125 He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B. BMC Pediatr 2022;22:426. [PMID: 35854256 DOI: 10.1186/s12887-022-03482-0] [Reference Citation Analysis]
126 Xiong S, Zhu D, Liang B, Li M, Pan W, He J, Wang H, Sutter K, Dittmer U, Lu M, Liu D, Yang D, Liu J, Zheng X. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine 2021;69:103464. [PMID: 34233260 DOI: 10.1016/j.ebiom.2021.103464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
128 Hong T, Yang H, Kao J. Role of HBsAg Testing in the Management of Patients with Chronic HBV. Curr Hepatology Rep 2019;18:331-41. [DOI: 10.1007/s11901-019-00484-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
129 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9. [PMID: 28335554 DOI: 10.3390/v9030056] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 24.0] [Reference Citation Analysis]
131 Wu Y, Wen J, Xiao W, Zhang B. Pregenomic RNA: How to assist the management of chronic hepatitis B? Rev Med Virol 2019;29:e2051. [PMID: 31074177 DOI: 10.1002/rmv.2051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
132 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
133 Wedemeyer H. The widespread rarity of HBsAg loss in chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:190-2. [PMID: 30679108 DOI: 10.1016/S2468-1253(18)30384-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Dimzova M, Bosilkovski M, Kondova-Topuzovska I, Gaseva M, Toshevki B, Petreska B, Jakimovski D. Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2019;7:2068-74. [PMID: 31456827 DOI: 10.3889/oamjms.2019.623] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Lai A, Sagnelli C, Presti AL, Cella E, Angeletti S, Spoto S, Costantino S, Sagnelli E, Ciccozzi M. What is changed in HBV molecular epidemiology in Italy? J Med Virol. 2018;90:786-795. [PMID: 29315661 DOI: 10.1002/jmv.25027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
136 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Reference Citation Analysis]
137 Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-puttini P, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:525-30. [DOI: 10.1016/j.jbspin.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
138 Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, Li Y, Manns MP, Lengauer T, Wedemeyer H, Kraft ARM, Falk CS, Cornberg M. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci Rep 2019;9:14118. [PMID: 31575964 DOI: 10.1038/s41598-019-50729-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
139 Liu C, Wu W, Shang S, Huang E, Xun Z, Lin J, Chen T, Yang B, Chen J, Ou Q. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens. J Med Virol 2019;91:249-57. [PMID: 30011350 DOI: 10.1002/jmv.25271] [Reference Citation Analysis]
140 Chan HLY. Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients-same score, different outcomes. Author's Reply. Aliment Pharmacol Ther 2018;48:876-7. [PMID: 30281836 DOI: 10.1111/apt.14961] [Reference Citation Analysis]
141 Lin J, Li J, Xie P, Han Y, Yu D, Chen J, Zhang X. Hepatitis B virus middle surface antigen loss promotes clinical variant persistence in mouse models. Virulence 2021;12:2868-82. [PMID: 34738866 DOI: 10.1080/21505594.2021.1999130] [Reference Citation Analysis]
142 Charre C, Levrero M, Zoulim F, Scholtès C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res 2019;169:104553. [PMID: 31288041 DOI: 10.1016/j.antiviral.2019.104553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
143 Wu Y, Zhu Z, Wu J, Bi W, Xu W, Xia X, Han D. Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml. Front Public Health 2021;9:633792. [PMID: 33981663 DOI: 10.3389/fpubh.2021.633792] [Reference Citation Analysis]
144 Chang HL, Wen WH, Lee CN, Chiu YE, Liu CJ, Chang MH, Lin LH, Chen HL. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate. J Viral Hepat 2021. [PMID: 34724288 DOI: 10.1111/jvh.13628] [Reference Citation Analysis]
145 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
147 Wang K, Xia Y, Zhu Y, Yu W, Guo Y, Liu L. Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. J Immunother Cancer 2021;9:e003195. [DOI: 10.1136/jitc-2021-003195] [Reference Citation Analysis]
148 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 30.0] [Reference Citation Analysis]
149 Xu W, Yu J, Wong VW. Mechanism and prediction of HCC development in HBV infection. Best Practice & Research Clinical Gastroenterology 2017;31:291-8. [DOI: 10.1016/j.bpg.2017.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
150 Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. HMER 2022;Volume 14:87-100. [DOI: 10.2147/hmer.s291976] [Reference Citation Analysis]
151 Mijočević H, Karimzadeh H, Seebach J, Usman Z, Al-Mahtab M, Bazinet M, Vaillant A, Roggendorf M. Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays. J Viral Hepat 2019;26:485-95. [PMID: 30450662 DOI: 10.1111/jvh.13044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Post G, Howell J, Sow A, Ndow G, Chemin I, Lo G, Cessay A, Cohen D, Njie R, Toure S, Diop M, Sombie R, Nana J, Leroy V, Lacombe K, Bojang L, Tacke F, Toure-Kane C, Ka M, Mendy M, Mboup S, Thursz M, Shimakawa Y, Ingiliz P, Lemoine M. Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. J Viral Hepat 2021;28:1003-10. [PMID: 33749097 DOI: 10.1111/jvh.13499] [Reference Citation Analysis]
153 Ferrando-Martinez S, Snell Bennett A, Lino E, Gehring AJ, Feld J, Janssen HLA, Robbins SH. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Front Immunol 2021;12:648420. [PMID: 34589081 DOI: 10.3389/fimmu.2021.648420] [Reference Citation Analysis]
154 Amini A, Varsaneux O, Kelly H, Tang W, Chen W, Boeras DI, Falconer J, Tucker JD, Chou R, Ishizaki A, Easterbrook P, Peeling RW. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis 2017;17:698. [PMID: 29143619 DOI: 10.1186/s12879-017-2772-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 10.4] [Reference Citation Analysis]
155 Ma G, Lou B, Lv F, Zhao D, Zhang Z, Chen Y. HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J Viral Hepat 2020;27:837-46. [PMID: 32277539 DOI: 10.1111/jvh.13299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
157 Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Danel C, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa. Liver Int 2019;39:280-9. [PMID: 30257068 DOI: 10.1111/liv.13975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
158 Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study group. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. J Infect Dis 2020:jiaa192. [PMID: 32318704 DOI: 10.1093/infdis/jiaa192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
159 Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, Tse YK, Wong VWS, Toyoda H. Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. J Gastroenterol Hepatol 2020;35:2202-9. [PMID: 32293740 DOI: 10.1111/jgh.15058] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Rattanachaisit P, Suksawatamnuay S, Sriphoosanaphan S, Thanapirom K, Thaimai P, Siripon N, Sittisomwong S, Poovorawan Y, Komolmit P. Stability of hepatitis B virus pregenomic RNA in plasma specimens under various temperatures and storage conditions. PeerJ 2021;9:e11207. [PMID: 33954043 DOI: 10.7717/peerj.11207] [Reference Citation Analysis]
161 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
162 Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14:657. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
163 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Reference Citation Analysis]
164 Shah PA, Choudhry S, Reyes KJC, Lau DTY. An update on the management of chronic hepatitis D. Gastroenterol Rep (Oxf) 2019;7:396-402. [PMID: 32494363 DOI: 10.1093/gastro/goz052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
165 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
166 Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol 2018;30:24-31. [PMID: 29453099 DOI: 10.1016/j.coviro.2018.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
167 Zhang L, Li MH, Cao WH, Qi TL, Lu Y, Wu SL, Hao HX, Shen G, Liu RY, Hu LP, Chang M, Hua WH, Song SJ, Wan G, Xie Y. Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection. Chin Med J (Engl) 2017;130:2697-702. [PMID: 29133758 DOI: 10.4103/0366-6999.218000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
168 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
169 Zimmer CL, Rinker F, Höner zu Siederdissen C, Manns MP, Wedemeyer H, Cornberg M, Björkström NK. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. The Journal of Infectious Diseases 2018;217:1656-66. [DOI: 10.1093/infdis/jiy097] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
170 Choi R, Oh Y, Park S, Lee SG, Lee EH. Understanding the patient population and test utilization for hepatitis B virus testing. J Clin Lab Anal 2019;33:e22987. [PMID: 31568619 DOI: 10.1002/jcla.22987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2019;26:1481-8. [PMID: 31446638 DOI: 10.1111/jvh.13195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
172 Ning J, Wang J, Zheng H, Peng S, Mao T, Wang L, Yu G, Liu J, Liu S, Zhang T, Ding S, Lu F, Chen X. Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups. Emerg Microbes Infect 2022;11:1356-70. [PMID: 35538876 DOI: 10.1080/22221751.2022.2071172] [Reference Citation Analysis]
173 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
174 Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Cornberg M, Enomoto M, Honda M, Zu Siederdissen CH, Ishigami M, Janssen HLA, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJH, Wang B, Wei L, Yang HI, Yano Y, Yatsuhashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin Gastroenterol Hepatol 2021;19:46-60.e8. [PMID: 32360825 DOI: 10.1016/j.cgh.2020.04.045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
175 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 2020;11:571166. [PMID: 33133084 DOI: 10.3389/fimmu.2020.571166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
177 Caviglia GP, Troshina Y, Garro E, Gesualdo M, Aneli S, Birolo G, Pittaluga F, Cavallo R, Saracco GM, Ciancio A. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. J Clin Med 2021;10:3308. [PMID: 34362093 DOI: 10.3390/jcm10153308] [Reference Citation Analysis]
178 Kuhnhenn L, Jiang B, Kubesch A, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH. Editorial: HBsAg serum levels in HBeAg-negative chronic HBV infection-is it a matter of genotype? Authors' reply. Aliment Pharmacol Ther 2018;48:103-4. [PMID: 29882986 DOI: 10.1111/apt.14793] [Reference Citation Analysis]
179 Chakrabarty G, Bruce M, Horner M, Wang B, Agarwal K, Carey I. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients? J Viral Hepat 2018;25:80-7. [PMID: 28710798 DOI: 10.1111/jvh.12756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Yu XQ, Wang MJ, Yu DM, Chen PZ, Zhu MY, Huang W, Han Y, Gong QM, Zhang XX. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients. J Clin Microbiol 2020;58:e00075-20. [PMID: 32554476 DOI: 10.1128/JCM.00075-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]